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SUMMARY
Interleukin-23 (IL-23) is a pro-inflammatory cytokine involved in the host defense against pathogens but is
also implicated in the development of several autoimmune disorders. The IL-23 receptor has become a
key target for drug discovery, but the exact mechanism of the receptor ligand interaction remains poorly un-
derstood. In this study the affinities of IL-23 for its individual receptor components (IL23R and IL12Rb1) and
the heteromeric complex formed between them have been measured in living cells using NanoLuciferase-
tagged full-length proteins. Here, we demonstrate that TAMRA-tagged IL-23 has a greater than 7-fold higher
affinity for IL12Rb1 than IL23R. However, in the presence of both receptor subunits, IL-23 affinity is increased
more than three orders of magnitude to 27 pM. Furthermore, we show that IL-23 induces a potent change in
the position of the N-terminal domains of the two receptor subunits, consistent with a conformational change
in the heteromeric receptor structure.
INTRODUCTION
Interleukin-23 (IL-23) is an important pro-inflammatory cytokine,
produced by antigen-presenting cells, such as dendritic cells
and macrophages, that plays a crucial role in host defense
against bacterial and fungal pathogens (Verreck et al., 2004;
Werner et al., 2011). IL-23 acts as a pre-requisite for the activa-
tion of T helper 17 (Th17) cells and has additional pro-inflamma-
tory effects on natural killer T, innate lymphoid, and gdT cell types
(Gaffen et al., 2014).
IL-23 is a disulfide-linked heterodimeric cytokine, an arrange-
ment unique to the IL-12 family, of which there are three other
reported members in man, IL-12, IL-27, and IL-35, with an addi-
tional member IL-39 identified in mice (Tait Wojno et al., 2019;
Wang et al., 2012). The heterodimer is formed of a single domain
four-helical bundle a subunit and a larger triplet domain b subunit
composed of two type III fibronectin domains and a single immu-
noglobulin-like domain (Hasegawa et al., 2016). The a and b sub-
units of the IL-23 heterodimer are IL23p19 and IL12p40, respec-
tively (Oppmann et al., 2000). The corresponding receptors for
the IL-12 cytokines are heteromers formed from different combi-
nations of five single transmembrane domain proteins. Each
IL-12 heteromeric receptor component is thought to have affinity
for a specific a or b subunit of each heterodimeric IL-12 family
cytokine (Hasegawa et al., 2016). The specific receptor for the
IL-23 cytokine is formed of the IL-12 receptor subunit b1
(IL12Rb1) and the IL-23 receptor (IL23R), which are both needed
for subsequent Janus kinase (JAK) activation and signaling (Par-
ham et al., 2002). The formation of heteromers by IL-12 family
cytokine receptors facilitates promiscuous pairing within the
IL-12 family, leading to a diverse range of functional effects
(Floss et al., 2020; Hasegawa et al., 2016). The archetypal
example of this promiscuity is the dual use of the IL12p40 cyto-
kine subunit and the IL12Rb1 receptor subunit in both the IL-23
and IL-12 cytokine receptor complexes (Parham et al., 2002).
Despite shared constituents, IL-23 and IL-12 mediate distinct
pathways, with IL-23 inducing the expansion and maintenance
of Th17 cells and IL-12, leading to differentiation of Th1 cells
(Vignali and Kuchroo, 2012).
Both IL-12 and IL-23 became a major focus for therapeutic
intervention when elevated expression of IL12p40 was observed
in autoimmune disorders (Fassbender et al., 1998; Shigehara
et al., 2003). This led to the first therapeutic to be developed
for intervention in the IL-12 and IL-23 signaling pathways to be
an anti-IL12p40 antibody (ustekinumab) (Benson et al., 2011).
Further research utilizing genome-wide association studies
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demonstrated links between single-nucleotide polymorphisms
in IL23p19 and IL23R and the incidence of ankylosing spondy-
litis, Crohn’s disease (CD), ulcerative colitis (UC), and psoriasis
among other disorders, identifying that IL-23 rather than IL-12
was involved in these diseases (Cargill et al., 2007; Dong et al.,
2013; Duerr et al., 2006). Further evidence from murine studies
demonstrated the IL-23 signaling pathway’s role in autoinflam-
mation (Cua et al., 2003; Langrish et al., 2005). Subsequently,
anti-IL23p19 inhibitors have been developed, and antibody ther-
apies are now licensed for the treatment of CD, UC, and psoria-
sis with ongoing trials for further autoinflammatory conditions
(Chyuan and Lai, 2020). The importance of the IL-23 signaling
pathway in other diseases has now been reported, including
for cancer (Ngiow et al., 2013) and cardiovascular disease (Ye
et al., 2020). Ustekinumab and other anti-IL23p19 inhibitors
have been highly effective for the treatment of autoimmune dis-
ease; however, these treatments are not without issues, which
include the reliance on administration by subcutaneous injection
and immunogenicity (Jullien et al., 2015). These problems have
led to the development of a class of small orally bioavailable pep-
tide inhibitors of the IL-23 receptor (Kong et al., 2020) such as
PTG-200, a competitive inhibitor of IL23R (Bourne, et al., 2016;
Cheng et al., 2019).
Despite the intense therapeutic focus on IL-23 and the wider
IL-12 family, there is a paucity of information regarding the spe-
cific mechanisms of the ligand-receptor interactions. The exact
regions of IL-23 that interact with its receptor have only been
defined relatively recently. Contrary to previous predictions
based on the assembly of the closely related IL-6 receptor com-
plex, the individual IL-23 receptor subunits appear to bind to
distinct a and b chains of IL-23 (Schroder et al., 2015). Two
recent studies have used X-ray crystallography to solve the
structures of the IL-23:IL23R and IL-23:IL23R:IL12Rb1(D1) com-
plexes, respectively, with the latter group also determining cryo-
genic electron microscopy structures for the extracellular do-
mains of IL-12 and IL-23 cytokine:receptor complexes (Bloch
et al., 2018; Glassman et al., 2021). This work and further muta-
tional studies demonstrated that IL-12 engages its receptor in a
similar way to IL-23, with IL12p40 binding IL12Rb1 and IL12p35
engaging IL12Rb2 (Esch et al., 2020; Glassman et al., 2021). As
part of the initial structural characterization of the IL23:IL23R
complex, the affinity of IL-23 was measured for the purified
extracellular domains of the IL-23 receptor using isothermal titra-
tion calorimetry (ITC). It was found that IL-23 has a higher affinity
for the truncated extracellular domain of IL23R than the equiva-
lent extracellular domain of IL12Rb1, leading to the suggestion
that the IL-23 receptor complex assembles via ligand-induced
dimerization, with IL-23 first binding IL23R followed by the
recruitment of IL12Rb1 by the IL23R:IL-23 complex (Bloch
et al., 2018).
To investigate the proposed model of IL-23 receptor complex
formation, we have used NanoLuciferase (NL) bioluminescence
resonance energy transfer (NanoBRET) (Machleidt et al., 2015;
Stoddart et al., 2015) to measure the binding of a tetramethylr-
hodamine (TAMRA)-labeled variant of IL-23 to individual full-
length IL-23 receptor subunits and heteromeric receptor
complexes in living cells. We have also measured the level of
constitutive association of receptor units and agonist-induced
changes in receptor subunit conformation utilizing dual-tagged
receptor variants that enable the measurement of intra-receptor
NanoBRET.
RESULTS
Characterization of IL23-TMR and IL-23 receptor
subunit fusion constructs
Preparation of fluorescently labeled IL-23 was carried out via in-
cubation of purified recombinant IL-23 with NHS-ester-linked
TAMRA. Following removal of the unreacted labeling reagent us-
ing a desalting column, the TAMRA-conjugated IL-23 (hereafter
referred to as IL23-TMR) and the unlabeled IL-23 were assessed
using liquid chromatography coupled with mass spectrometry
(LC-MS; Figures S1 and S2). This analysis revealed that both
the labeled and unlabeled cytokine samples were heterodimeric
and uncontaminated with IL12p40 or IL23p19 monomers (Fig-
ure S2B). Furthermore, upon the application of dithiothreitol
(DTT), the protein could be split into its constituent monomers
by reduction of the linking disulfide bond (Figures S1 and S2).
While the IL23p19 subunit closely matched its predicted molec-
ular weight, the IL12p40 subunit gave several peaks differing by
162 Da, all with masses higher than that predicted from the pro-
tein’s amino acid sequence (Table S1). This most likely corre-
sponded to varying levels of post-translational modification
(PTM) by N-linked glycosylation, a modification that has been
previously reported for the IL12p40 subunit (Bohnacker et al.,
2020). The unlabeled IL-23 heterodimeric complex exhibited
the previously described heterogeneous pattern, with the most
abundant peak corresponding to a 56,050-Da species
(Figure S2).
In the IL23-TMR sample the most abundant species remained
the unlabeled IL-23 at 56,050 Da; however, a single TAMRA-
labeled 56,461-Da species and a double-labeled 56,876-Da
species were also present. Trace amounts of three and four
labeled species were also apparent from low-abundance peaks
at 57,287 and 57,702 Da, respectively (Figure S2). Reduction of
the IL23-TMR sample with DTT revealed that the IL23p19 sub-
unit was labeled to a greater extent than the IL12p40 subunit
(Figure S2A), with peak intensity analysis demonstrating that
64.9% of TAMRA labels were located on IL23p19. The primary
constituents of the heterodimeric IL23-TMR fraction were deter-
mined by the relative abundance of themost intense PTM variant
to be 52.3% unlabeled, 29.5% single labeled, and 18.2% double
labeled.
To gain a further quantitative measure of the constituents of
the labeled IL-23 mixture, we used fluorescence correlation
spectroscopy (FCS) (Briddon et al., 2004) essentially as
described by Kilpatrick et al. (2017). To measure the concentra-
tion of TAMRA-labeled particles in solution, we collected FCS
fluctuations from freely diffusing IL23-TMR in a confocal mea-
surement volume (Figure 1A). Subsequent autocorrelation anal-
ysis (Figure 1B), allowed calculation of the concentration of
fluorescent particles (Briddon et al., 2004; Kilpatrick et al.,
2017). Measured IL23-TMR concentrations were substantially
lower than predicted, but the addition of 1 mg/mL BSA, which
prevents non-specific interactions of the protein with the plate
(Kilpatrick et al., 2017), increased the observed concentration
(Figure 1D). Consequently, 1 mg/mL BSA was included
in all subsequent IL-23 and IL23-TMR experiments. FCS
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measurements of IL23-TMR in the presence of BSA displayed a
single diffusing species with a diffusion coefficient of 37.9 ±
1.8 mm2/s while that for TAMRA alone was 280 mm2/s. By
comparing the measured concentration of this IL23-TMR fluo-
rescent species with the total concentration of IL-23 measured
in the sample via absorbance at 280 nm, it was demonstrated
that 51.5% of the IL-23 in the sample was fluorescently labeled
with TAMRA.
The ratio of mono- to multi-labeled IL23-TMR particles was
determined by calculating the average molecular brightness of
individual fluorescent particles using a two-component
photon-counting histogram analysis from the same intensity
fluctuations (Chen et al., 1999; Figure 1C). It was found that the
IL23-TMR fraction was 77% composed of a 163,983 ± 2,537
cpm/s brightness fraction and 23% composed of a 589,772 ±
5,557 cpm/s brightness fraction. The brightness of unconjugated
TAMRA under these conditions was determined to be 301,461 ±
10,764 cpm/s. As the LC-MS spectra showed that themajority of
labeled IL-23 is bound to just one TAMRAmolecule, this demon-
strated that reaction of the fluorophore with IL-23 caused signif-
Figure 1. Characterization of labeled IL23-
TMR using fluorescence correlation spectros-
copy and photon-counting histogram analysis
(A) Example of the fluorescence fluctuations ob-
tained over time for 100 nM IL23-TMR in the pres-
ence of 1 mg/mL BSA.
(B) Autocorrelation curves for four concurrently
collected replicate fluorescence correlation spec-
troscopy (FCS) readings of 100 nM IL23-TMR in the
presence of 1 mg/mL BSA, with a red line denoting
the one-component free 3D fit of the data.
(C) Photon-counting histogram (PCH) of the data
presented in (B) fit with a two-component model (red
line).
(D) Analysis of IL23-TMR showing the concentration
of TAMRA-labeled molecules measured by FCS in
(B) versus the total concentration of IL-23 (initially
quantified by absorbance at 280 nm), in the pres-
ence (red) or absence (blue) of 1 mg/mL BSA. Di-
agonal dotted line represents x = y. Each data point
represents mean value ± SEM of 20 measurements
from five independent experiments.
(E) Proportion of labeled IL-23 species. Total con-
centration of IL-23 was quantified by UV absor-
bance at 280 nm, and total concentration of
TMR-labeled IL-23 was determined using the auto-
correlation analysis demonstrated in (B). The pro-
portion of different populations of labeled species
was quantified using the two-component PCH
analysis demonstrated in (C). Data shown are
mean ± SEM of values obtained in five independent
experiments.
icant quenching of its brightness, with a
mean value almost 2-fold lower than that
of unbound TAMRA. The second bright-
ness component likely represents a
mixture of IL-23 species, bound to two or
more TAMRA molecules with a mean
brightness formed both from variable label
number and differing degrees of fluores-
cence quenching. As a result these components are hereafter
referred to asmono- andmulti-labeled IL-23. The overall propor-
tions of these components when compared with the previously
established total labeled IL-23 concentration were determined
to be 39.6% mono-labeled and 11.9% multi-labeled IL-23, with
a remaining 48.5% of the mixture being made up of unlabeled
IL-23 (Figure 1B).
Cell surface expression of NL fusions of IL23R and IL12Rb1 in
HEK293T cells was confirmed using luminescence imaging and
anti-NL immunocytochemical imaging, which showed that NL
constructs were localized to the plasma membrane (Figure 2).
Cell surface expression of HT-IL12Rb1 and SNAP-IL12Rb1
was confirmed by imaging cells expressing these constructs,
which had been labeled by incubation with AlexaFluor 488
(AF488)-fused HaloTag or SNAP-tag substrate (Figure S3).
To calibrate NL luminescence and AF488 fluorescent intensity
values in order to estimate expression levels, we made up and
measured a standard curve of both purified NL and SNAP-
AF488 substrate according to the same protocol that would be
used in further experiments (Figure S4).
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To ascertain whether the fusion of NL to IL23R or the fusion of
SNAP-tag or HaloTag to IL12Rb1 had any effect on IL-23-
induced signaling in HEK293T cells, we monitored phosphoryla-
tion of the downstream signal transducer and activator of
transcription 3 (STAT3) transcription factor. Co-expression of
the wild-type IL23R heteromer (IL23R and IL12Rb1), followed
by stimulation with varying concentrations of IL-23, led to deter-
mination of an EC50 = 269 ± 106 pM (n = 4) for cytokine stimula-
tion of phosphorylated STAT3 (pSTAT3). This experiment was
replicated utilizing co-transient transfections of either NL-IL23R
and IL12Rb1 or NL-IL23R and SNAP-tag fused IL12Rb1
(SNAP-IL12Rb1) or NL-IL23R andHaloTag fused IL12Rb1, which
led to the determination of potency values of 154 ± 46 pM (n = 4),
150 ± 43 pM (n = 4), and 199 ± 33 pM, respectively, for IL-23
stimulation of pSTAT3 (Figure 3). These results demonstrated
that use of these fusion constructs did not significantly alter
signal transduction induced by IL-23 (p > 0.05; one-
way ANOVA).
Binding of IL23-TMR to IL12Rb1, IL23R, and heteromers
of both receptor subunits
The binding of IL23-TMR was measured using NanoBRET in
HEK293T cells transiently expressing NL fusions of IL23R or
IL12Rb1 in the presence and absence of the corresponding un-
Figure 2. Expression of NanoLuciferase-tagged
IL23R and IL12Rb1 constructs
(A) Bright-field (top) and luminescence images (bottom)
of HEK293T cells expressing NL-IL12Rb1, NL-IL23R,
and NL-IL23R co-expressed with IL12Rb1 (collected
with an Olympus LV200 Bioluminescence microscope).
A 3-s exposure was used for NL-IL12Rb1 transfected
cells and a 10-s exposure for the other conditions. Im-
ages are representative of those collected in five inde-
pendent experiments and were collected on the same
experimental occasion. Scale bar represents 50 mm.
(B) Immunocytochemical imaging of transfected
HEK293T cells labeled with an anti-NanoLuciferase
antibody. Images are presented with (bottom) and
without (top) Hoechst staining and are representative of
those taken in three independent experiments. Images
were taken on the same experimental day. Scale bar
represents 20 mm.
tagged co-receptor. Increasing concentrations
of IL23-TMR resulted in an increase in the
BRET signal that was composed of saturable
specific and linear non-specific binding com-
ponents (Figure 4). Non-specific binding was
determined in the presence of an excess of un-
labeled IL-23; 1 mMwas used for NL-IL23R and
NL-IL12Rb1 transfected cells and 50 nM was
used for NL-IL23R co-expressed with
IL12Rb1. IL23-TMR had a greater affinity for
NL- IL12Rb1 (KD = 30.1 ± 5.5 nM; n = 5) than
NL-IL23R (KD = 222.2 ± 71.1 nM; n = 5) when
the constructs were expressed in isolation
(Figures 4A and 4B). However, when NL-
IL23R was co-expressed with unlabeled
IL12Rb1, the dissociation constant of IL23-
TMR to the heteromeric receptor complex was markedly
decreased to 27.0 ± 3.6 pM (n = 5), which was significantly
different from the affinity of IL23-TMR to cells expressing NL
fused monomers (unpaired t test; Figure 4C).
The dissociation constant obtained for IL23-TMR binding to
NL-IL12Rb1 in the presence of unlabeled IL23R was higher
(46.7 ± 16.1 nM, n= 3; Figure 5B) and similar to the value obtained
with NL-IL12Rb1 alone. However, comparison of the lumines-
cence intensities of cells expressing NL-IL12Rb1 and NL-IL23R
indicated that NL-IL12Rb1 achieved a much higher expression
level in transient transfections than that obtained with NL-IL23R
(0.0518 ± 0.0066 versus 0.0125 ± 0.0027 pmol/well, respectively;
Figure 5A). The higher dissociation constant obtained for NL-
IL12Rb1 in the presence of unlabeled IL23R is therefore likely to
be a consequence of the NL-IL12Rb1:IL23R complex only repre-
senting a small proportion of the total binding of IL23-TMR to NL-
IL12Rb1. To investigate this further, we undertook transfections
using a lower (1:10) transfection ratio of NL-IL12Rb1 and IL23R.
The affinity of IL23-TMR under these conditions was 19-fold
higher (KD = 647 ± 79.5 pM, n = 5; Figure 5B) and consistent
with a higher proportion of NL-IL12Rb1:IL23R complexes pre-
sent under these experimental conditions.
To ascertain whether the fusion of N-terminal tags to IL12Rb1
blocked the binding of IL23-TMR, BRET binding experiments
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analogous to those previously detailed were carried out using
cells expressing NL-IL23R and HT-IL12Rb1 or SNAP-IL12Rb1.
IL23-TMR bound to cells expressing both receptor fusion con-
structs with an affinity of 179 ± 8 pM and 454 ± 43 pM to
the HT-IL12Rb1 and SNAP-IL12Rb1 conditions, respectively
(Figure S5).
Binding affinity of unlabeled IL-23 for the NL-
IL23R:IL12Rb1 receptor complex
To measure the affinity of unlabeled IL-23 for the IL-23 receptor
complex, we undertook NanoBRET competition experiments us-
ing NL-IL23R and IL12Rb1 co-transfected into HEK293T cells.
This assay was carried out using several concentrations of
IL23-TMR and increasing concentration of unlabeled IL-23,
whereby the IC50 determined for unlabeled IL-23 was shifted to
higher concentrations (with increasing concentrations of IL23-
TMR) consistent with a competitive interaction (Figures 6A and
6B; Cheng and Prusoff, 1973). However, at the highest concen-
tration of IL-23 used (3 nM) the decrease in potency reached a
limiting value indicative of a more complex interaction (Figures
6A and 6B). Analysis of the data obtained with lower concentra-
tions of IL23-TMR yielded a mean Ki for IL-23 of 31.6 ± 7.7 pM
(n = 13), which was not significantly different from the pre-deter-
mined value for the KD of IL23-TMR (unpaired t test). In addition, a
Ki IL-23 of 27.2pMandaKD IL23-TMRof 35.1pMwereobtained from
a linear plot of the relationship between IL23-TMR concentration
and the corresponding IC50 values of unlabeled IL-23 (Figure 6B).
IL-23-induced changes in the position of the N termini of
IL12Rb1 and IL23R
To ascertain the level of constitutive association between
IL12Rb1 and IL23R, we transfected HEK293T cells with varying
concentrations of N-terminal fused SNAP-IL12Rb1 plasmid
with a constant concentration of NL-IL23R plasmid. The BRET
signal between NL and AF488 bound to the SNAP-tag was
then measured in the presence and absence of 5 nM IL-23.
BRET was observed between the subunits both with and without
IL-23, with the signal amplitude in the absence of IL-23 being
54.5% ± 3.9% that of the signal with IL-23. The BRET signal
was saturable with increasing SNAP-IL12Rb1 plasmid concen-
tration (Figure 7A); however, the level of SNAP-IL12Rb1 expres-
sion increased in a linear fashion with plasmid concentration
(Figure 7B), as quantified by fluorescent intensity measurements
before substrate addition. This demonstrated that the increase in
BRET signal was due to specific interactions of the constructs
rather than non-specific BRET in the membrane. The BRET ratio
obtained for the interaction between NL-IL23R and SNAP-
IL12Rb1 was significantly increased by 5 nM IL-23 (p < 0.0001;
t test). The ng of SNAP-IL12Rb1 cDNA transfected per well could
be further transformed into the pmol/well of SNAP-IL12Rb1
construct through the use of the SNAP-tag AF488 curve outlined
in Figure S4. This transformation (Figures 7C and 7D) enabled the
calculation of the BRET50 values of 0.0167 ± 0.0094 and 0.0840 ±
0.0409 pmol/well SNAP-IL12Rb1 per well in the presence and
absence of 5 nM IL-23, respectively.
To determine how the receptor subunit proximity or orienta-
tion changed during the formation of the ligand-bound IL-23 re-
ceptor complex, we carried out a BRET assay whereby
HEK293T cells were co-transfected with equal concentrations
of NL-IL23R and N-terminal SNAP-tag or HaloTag fused
IL12Rb1. The receptor was fluorescently labeled by addition
of SNAP-tag AF488 substrate to the SNAP-tag or HaloTag
618 (HT618) ligand to the HaloTag. In both the SNAP-tag and
HaloTag-IL12Rb1 conditions there was a clear change in
BRET ratio after incubation with increasing concentrations of
unlabeled IL-23 (Figure 7D). The EC50 values of IL-23 for
these responses were 42.9 ± 10.3 pM (n = 5) and 43.6 ± 15.8
pM (n = 5) for the SNAP-tag and HaloTag assays, respectively
(no statistical difference; unpaired t test; Figure 7D). However,
while the SNAP-IL12Rb1 assay gave an increase in BRET
signal following addition of IL-23, in the HaloTag-IL12Rb1 assay
the BRET signal decreased with increasing concentrations of
IL-23 (Figure 7E). A comparable BRET assay was also estab-
lished using HEK293T cells transfected with both NL-IL12Rb1
and HaloTag-IL23R. This assay demonstrated an increase in
BRET with increasing concentrations of IL-23 but gave a higher
EC50 value of 457 ± 209 pM (Figure S6). Taken together, these
data are consistent with a change in conformation of the IL23-
R:IL12Rb1 complex rather than an increase in the formation of
these complexes following agonist addition.
DISCUSSION
The IL-23 cytokine and its receptor are important therapeutic tar-
gets (Verreck et al., 2004; Werner et al., 2011). However, many
aspects relating to the mechanisms by which the IL-23:IL23R:
IL12Rb1 protein complex is formed remain to be fully elucidated.
In the present study, NanoBRET was utilized to measure the af-
finity of fluorescently labeled IL-23 to NL fusions of the full-length
individual IL-23 and IL12Rb1 receptor subunits and the full-
length IL-23 receptor heteromeric complex in living cells.
Figure 3. The effect of N-terminal NanoLuciferase, HaloTag, or
SNAP-tag additions to IL-23 receptor subunits on IL-23-induced
STAT3 phosphorylation
STAT3 phosphorylation induced in HEK293T cells transfected with different
tagged variants of the IL-23 receptor after a 30-min incubation with increasing
concentrations of IL-23. Data are expressed as a percentage of the response
obtained with 15 nM IL-23. Values are mean ± SEM from four or three (NL-
IL23R and HT-IL12Rb1) independent experiments.
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A previous study that characterized the interaction of IL-23
with the purified extracellular domains of the IL23R and
IL12Rb1 receptor subunits using ITC indicated that IL-23 has a
much higher affinity for the extracellular domain of IL23R
(44 nM) than the extracellular domain of IL12Rb1 (2 mM) (Bloch
et al., 2018). These observations led Bloch and colleagues to
suggest that the binding of IL-23 involved a sequential mecha-
nism whereby IL-23 binds first to the IL23R subunit and then in-
duces a dimerization step between the IL23R:IL-23 complex and
IL12Rb1, leading to the final complex (Bloch et al., 2018).
In the present study, we determined that the dissociation con-
stant of IL23-TMR binding to full-length cell surface-expressed
NL-IL23R was 222.2 ± 71.1 nM. However, the dissociation con-
stant of IL23-TMR binding to the full-length NL-IL12Rb1 in intact
cells was 30.1 ± 5.5 nM. This is nearly an order of magnitude
lower than the value obtained for IL23R and suggests that the
sequence of events identified by Bloch et al. (2018) may need
to be re-evaluated. The higher affinity of IL23-TMR for IL12Rb1
in live cells is also consistent with previous reports that cells ex-
pressing IL12Rb1 have a 2- to 5-nM affinity for the IL-12 cytokine
(Chua et al., 1994). This observation is pertinent to the current
study, given that IL-12 and IL-23 heteromers share the IL12p40
cytokine subunit and have both been shown to engage their re-
ceptors in a similar manner (Glassman et al., 2021).
When NL-IL23R was co-expressed in cells alongside unla-
beled IL12Rb1, the affinity for IL23-TMRwas increased by nearly
four orders of magnitude to 27.0 ± 3.6 pM. This suggests that a
Figure 4. Binding of IL23-TMR toNL-IL12Rb1,
NL-IL23R, and NL-IL23R co-expressed with
untagged IL12Rb1
(A–C) Binding of increasing concentrations of IL23-
TMR to HEK293T cells expressing either (A) NL-
IL23R, (B) NL-IL12Rb1, or (C) NL-IL23R and IL12Rb1
in the presence (red) or absence (blue) of an excess
of unlabeled IL-23. The concentration of unlabeled
IL-23 used was 1 mM (A and B) and 50 nM (C). Data
points are mean raw BRET ratio values ± SEM from
five independent experiments.
(D) The combined specific binding data from (A) to
(C) after subtraction of non-specific binding.
third, high-affinity binding site for IL23-
TMR is formed by oligomeric complexes
containing both IL23R and IL12Rb1 on
the cell surface. To further characterize
this third binding site, we measured the af-
finity of unlabeled IL-23 in cells expressing
both NL-IL23R and IL12Rb1 using a
competition binding assay. The results of
these competition experiments confirmed
that the IL-23:IL12Rb1 complex had a
high affinity for the untagged IL-23 cyto-
kine, KD = 27.2 ± 12.0 pM, which was
similar to that measured for IL23-TMR. In
the context of a growing list of reported
IL23R antagonists (Cheng et al., 2019;
Kong et al., 2020; Kuchar et al., 2014; Pan-
dya et al., 2020; Quiniou et al., 2014), this
assay should be a useful tool for future
screening efforts to identify and develop IL-23 receptor
inhibitors.
To determine whether IL23R and IL12Rb1 proteins can form
constitutive heterodimers in the absence of ligand in HEK293T
cells, and to what extent this is influenced by agonist treatment,
we compared BRET measures between NL-tagged IL23R and
a fluorescently labeled SNAP-tag fusion of IL12Rb1. These ex-
periments demonstrated that IL12Rb1 and IL23R can form di-
mers in the absence of IL-23, as demonstrated by the saturable
increase in BRET ratio obtained with increasing amounts of
transfected SNAP-IL12Rb1. Furthermore, following the addition
of IL-23 (5 nM) there was an increase in the BRET ratio ob-
tained for the interaction between NL-IL23R and SNAP-
IL12Rb1. Addition of IL-23 produced a concentration-depen-
dent increase in BRET ratio in HEK293T cells transfected with
a 1:1 ratio of NL-IL23R and SNAP-IL12Rb1. This interaction
had an EC50 value of 42.9 pM that corresponded well with
the high-affinity binding site measured in IL-23 competition as-
says (KD = 31.6 pM) when both NL-IL23R and IL12Rb1 were
expressed together in the same cells. However, while in the
SNAP-IL12Rb1 assay the BRET signal increased with IL-23
binding, in the HaloTag-IL12Rb1 assay the BRET signal
decreased following agonist binding. The IC50 value for this
inhibitory effect of IL-23 was very similar (43.6 pM) to the
EC50 value obtained for the increase in BRET signal in the
SNAP-IL12Rb1 assay. Furthermore, when the HaloTag was
placed on IL23R and the NL tag was added to IL12Rb1, this
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IL-23-induced decrease in BRET was changed to a large in-
crease in the BRET signal.
The resonance energy transfer that occurs between two
labeled proteins depends very much on both proximity
(<10 nm) and orientation of the acceptor and donor species
(Dacres et al., 2012). In the case of receptors that are labeled
with both a donor and acceptor species, this can lead to
agonist-induced increases or decreases in BRET as a conse-
quence of conformational changes induced by agonist binding.
This has been demonstrated particularly well with intra-molec-
ular FRET sensors for G-protein-coupled receptors (Perpiñá-Vi-
ciano et al., 2020). Taken together, the data obtained for IL-
23:IL12Rb1 oligomerization indicates that binding of IL-23 to
a high-affinity binding site formed by the oligomeric complex
triggers a conformational change in the N-terminal domains
of the IL-23 receptor components. This is the simplest explana-
tion for the positive and negative BRET signals obtained
following IL-23 addition for the interaction between IL23R and
IL12Rb1 with different tag arrangements. The SNAP-tag is a
19.4-kDa protein and the HaloTag is a 33-kDa protein (Crivat
and Taraska, 2012), so it is very likely that their orientation
with respect to the 19-kDa NL on NLuc-tagged proteins can
change in different ways as a result of conformational changes
induced by IL-23.
We observed a decrease in the potency of IL-23-induced
conformational change when using cells transfected with the
HT-IL23R and NL-IL12Rb1 tagging conformation; however, for
cells transfected with the constructs NL-IL23R and SNAP-
IL12Rb1 we measured no change in the potency of IL-23-
induced STAT phosphorylation compared with the untagged
control. Notwithstanding any subtle effects of the NL fusions
and fluorescent labeling on IL-23 binding affinity, it is clear that
the NanoBRET technique has enabled the detection of binding
events that are at a far higher order of affinity than any of those
previously measured at the receptor using untagged but trun-
cated purified protein (Bloch et al., 2018). Furthermore, we
have shown that SNAP fusions of IL12Rb1 and NL fusions of
IL23R do not abrogate the ability of the receptor to initiate signal
transduction through the phosphorylation of STAT3. The high-af-
finity binding site identified in this work is in agreement with the
EC50 values we measured for downstream phosphorylation of
STAT3 and others measured for the IL-23-induced phosphoryla-
tion of STAT5 (EC50 = 28 pM; Varghese et al., 2020).
A consensus mechanism of receptor activation for the wider
IL-12 cytokine family of receptors has yet to be elucidated.
Within the cytokine receptor family, initial suggestions of
ligand-induced dimerization (Cochet et al., 1988) have been su-
perseded in many instances by a mechanism involving
Figure 5. Impact of expression level on
ligand-binding characteristics of NL-
IL12Rb1
(A) Luminescence signal measured from HEK293T
cells following transient transfection. Correspond-
ing NL (pmol/well) levels are calculated from a
purified NL standard curve (Figure S4). Values are
expressed as mean ± SEM from five or three (1:1
NL-IL12Rb1 + IL23R) independent experiments.
(B) Binding of IL23-TMR to combinations of NL-
IL12Rb1 and IL23R at different transfection ratios in
HEK293T cells. Values show mean ± SEM cells of
the BRET ratios obtained after subtraction of non-
specific binding. The concentration of IL-23 used
to define non-specific binding was 1 mM (blue and
green) and 100 nM (red). Data were obtained from
three (green) or five (red and blue) separate ex-
periments. The data for 1:1 NL-IL12Rb1 + IL23R
(green circles) were fitted to a two-site binding
curve, which yielded KD values of 28 pM and 72 nM with the high-affinity site accounting for 16.2% of the maximum specific binding. For these data, the two-
site binding curve was a significantly better fit than to a single-site saturation curve (p < 0.0001; partial F test).
Figure 6. Determining the affinity of unla-
beled IL-23 for the IL-23 receptor
(A) HEK293T cells expressing NL-IL23R and
IL12Rb1 were incubated with varying concentra-
tions of IL23-TMR as shown in the bar chart (left) and
increasing concentrations of unlabeled IL-23 (right).
Data represent mean ± SEM of the raw BRET ratios
obtained from five independent experiments.
(B) IL-23 IC50 values derived in (A) plotted against the
buffer concentration of IL23-TMR, with all points
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conformational change and the presence of pre-formed inactive
dimeric receptor complexes (Chua et al., 1994; Gent et al., 2002;
Couturier and Jockers, 2003; Schuster et al., 2003). These re-
ceptors can then be activated by a rotation of the transmem-
brane domains (reviewed by Maruyama, 2015), which results in
a rearrangement of pre-dimerized trans-inhibiting JAKs allowing
phosphorylation and signaling (Waters et al., 2014). If this is the
case for the IL-23 receptor, it is unlikely that the interaction oc-
curs within the extracellular domains of the receptor subunits
alone, as it has previously been demonstrated that purified
IL23R and IL12Rb1 extracellular domains have no affinity for
each other (Bloch et al., 2018) and even that these domains
can be replaced entirely by nanobodies and still initiate signaling
with the addition of a synthetic dual antigenic ligand (Engelowski
et al., 2018).
While the present study contradicts the previous report of the
ligand-induced dimerization of the IL-23 receptor, there is evi-
dence to support the existence of pre-dimerized receptor com-
plexes at the IL-23 receptor, within the wider IL-12 family and at
other closely related receptors. Sivenesan and colleagues used
IL-23 receptor C-terminal fusions of split Renilla luciferase ex-
pressed in HEK293 cells to demonstrate luminescence in the
absence of IL-23 and used this as evidence to argue that the
IL-23 receptor is constitutively associated in the absence of
ligand, similarly to the related erythropoietin receptor (Remy
et al., 1999; Sivanesan et al., 2016).
The initial study outlining the discovery of the IL-12 receptor
reported cytokine binding sites of three different affinities on
live cells, and the authors proposed that the highest-affinity
5- to 20-pM site was formed by a pre-formed receptor dimer
(Chua et al., 1994). In addition, the deletion of the extracellular
stalk region of IL23R has been shown to cause the formation
of IL23R receptor subunit complexes that signal in the absence
of ligand (Hummel et al., 2017); this could be evidence for an
inhibitory domain that ordinarily prevents signaling in constitu-
tively formed dimers. The closely related IL-6 receptor, which in-
cludes a gp130 subunit highly homologous to IL12Rb1 (Chua
et al., 1994), has also been shown to undergo ligand-indepen-
dent dimerization (Schuster et al., 2003).
This study has outlined the application of a proximity-based
technique for the IL-12 cytokine family. This approach could
be further developed to gain insights into the kinetics of cyto-
kine binding and receptor assembly and be used to assess
any differences in interactions caused by disease-relevant
mutations. The successful application of this technology to
the IL-23 receptor also highlights its utility to measure similar
interactions at other related cytokine receptors that remain
equally underinvestigated, with IL-12 being the only one of
the four IL-12 family cytokines to have a reported cellular af-
finity (Chua et al., 1994).
The IL-23 cytokine and its receptor are a target of high thera-
peutic interest. However, the binding mechanism, an important
piece of information for drug discovery, has not yet been defined
on living cells. This study defines the affinity of IL-23 to its full-
length receptor in living cells, demonstrating that the current
ligand-induced dimerization hypothesis of IL-23 receptor as-
sembly is unlikely and that a conformational change-based
activation mechanism is the more probable situation. The
Figure 7. Association of IL12Rb1 and IL23R in
the absence of IL-23 with changes in the posi-
tion of the N-terminal regions of IL12Rb1 and
IL23R following binding of IL-23
(A) Effect on the BRET signal of transfecting
increasing concentrations of SNAP-IL12Rb1 with
50 ng of NL-IL23R into cells. The SNAP-IL12Rb1
was labeled with SNAP-tag-AF488 substrate and
BRET between NL-IL23R and SNAP-IL12Rb1 was
then monitored in the presence or absence of 5 nM
IL-23. Data are Mean ± SEM from five independent
experiments. The BRET signal was normalized to
cells expressing NL-IL23R in isolation.
(B) Fluorescence intensity signals from laser-excited
SNAP-tag bound AF488 taken before the BRET
readings in (A), normalized to the fluorescence in-
tensity signal of cells expressing NL-IL23R in
isolation.
(C and D) Data shown in (A) and (B), respectively with
the x axis transformed to pmol/well SNAP-IL12Rb1
as calculated from the normalized fluorescent in-
tensity values using an SNAP-AF488 substrate
standard curve (Figure S4).
(E) Intra-receptor BRET between HT618-IL12Rb1
(green) or SNAP488-IL12Rb1 (blue) co-expressed
with NL-IL23R on HEK293T cells after incubation
with increasing concentrations of unlabeled IL-23.
Data show mean ± SEM of background-corrected
BRET signals from five independent experiments.
(F) Data from (E) normalized to percentage of the
maximum inhibition or induction of BRET.
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implications of this are that two further protein-protein interac-
tion sites could exist for drug discovery, firstly the dimeric IL23R:
IL12Rb1 interface with IL-23 and secondly the IL23R interface
with IL12Rb1.
SIGNIFICANCE
The IL-23 receptor is an important therapeutic target for
autoinflammatory conditions such as Crohn’s disease and
psoriasis; however, the mechanism of receptor activation
has yet to be fully defined. Using NanoBRET we measured
the interaction of IL23-TMRwith NL fusions of the full-length
IL-23 receptor subunits expressed in cells and report that
IL23-TMR had a higher affinity for NL-IL12Rb1 compared
with that for NL-IL23R. In addition, we observed that co-
expression of NL-IL23R with IL12Rb1 created a binding
site with an affinity far higher than those measured for NL-
IL23R or NL-IL12Rb1 alone. This heteromeric complex could
be formed in the absence of added ligand, suggesting that
this high-affinity binding site was constitutively present.
Furthermore, the impact of IL-23 addition on the position
of N-terminal regions of the constituent protomers was
dependent on the nature of the tags used but was consistent
with an IL-23-mediated change in receptor conformation.
These results together suggest that IL-23 binds to pre-
formed heteromers of both IL23R and IL12Rb1, leading to
a conformational change. This finding is significant, as it
has been reported that the IL-23 receptor is activated by
ligand-induced dimerization with initial binding to the
IL23R subunit. The findings of this study have direct implica-
tions for drug discovery both by outlining a methodology
through which to characterize IL-23 receptor antagonists
and by revealing that the IL23R:IL12Rb1 interface could be
a good target to disrupt IL-23 receptor heteromer formation
and signaling.
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Sı́pová, H., Schneider, B., Homola, J., Sebo, P., et al. (2014). Human inter-
leukin-23 receptor antagonists derived from an albumin-binding domain scaf-
fold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells.
Proteins 82, 975–989.
Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B.,
Sedgwick, J.D., McClanahan, T., Kastelein, R.A., and Cua, D.J. (2005). IL-23
drives a pathogenic T cell population that induces autoimmune inflammation.
J. Exp. Med. 201, 233–240.
Machleidt, T., Woodroofe, C.C., Schwinn, M.K., Méndez, J., Robers, M.B.,
Zimmerman, K., Otto, P., Daniels, D.L., Kirkland, T.A., and Wood, K.V.
(2015). NanoBRET—a novel BRET platform for the analysis of protein-protein
interactions. ACS Chem. Biol. 10, 1797–1804.
Maruyama, I.N. (2015). Activation of transmembrane cell-surface receptors via
a common mechanism? The ‘‘rotation model’’. BioEssays 37, 959–967.
Ngiow, S.F., Teng, M.W.L.L., and Smyth, M.J. (2013). A balance of interleukin-
12 and -23 in cancer. Trends Immunol. 58, 1208–1216.
Oppmann, B., Lesley, R., Blom, B., Timans, J.C., Xu, Y., Hunte, B., Vega, F.,
Yu, N., Wang, J., Singh, K., et al. (2000). Novel p19 protein engages IL-
12p40 to form a cytokine, IL-23, with biological activities similar as well as
distinct from IL-12. Immunity 13, 715–725.
Pandya, P., Sayers, R.O., Ting, J.P., Morshedian, S., Torres, C., Cudal, J.S.,
Zhang, K., Fitchett, J.R., Zhang, Q., Zhang, F.F., et al. (2020). Integration of
phage and yeast display platforms: a reliable and cost effective approach
for binning of peptides as displayed on-phage. PLoS One 15, e0233961.
Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J.,
Pflanz, S., Zhang, R., Singh, K.P., Vega, F., et al. (2002). A receptor for the het-
erodimeric cytokine IL-23 is composed of IL-12R 1 and a novel cytokine recep-
tor subunit, IL-23R. J. Immunol. 168, 5699–5708.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit Anti-NanoLuciferase Promega Corporation Gifted by Promega
AF488 Chicken Anti-Rabbit ThermoFisher Scientific Cat# A-21441; RRID: AB_2535859
Chemicals, peptides, recombinant proteins
HaloTag NanoBRET 618 Ligand Promega Corporation Cat# G9801
SNAP-tag AlexaFluor 488 membrane
impermeant substrate
New England BioLabs Cat# S9124S




ThermoFisher Scientific Cat# C300
TAMRA, SE; 5-(and-6)-
Carboxytetramethylrhodamine,
Succinimidyl Ester (5(6)-TAMRA, SE),
mixed isomers
ThermoFisher Scientific Cat# C1171
Recombinant IL-23 protein GlaxoSmithKline (internal) Gifted by Surjit Bains
FuGENE HD Promega Cat# E2312
Fetal Bovine Serum Sigma Aldrich Cat# F2442
Protease-free Bovine Serum Albumin Sigma Aldrich Cat# A7030
Dulbecco’s Modified Eagle’s Medium Sigma Aldrich Cat# D6429
Poly-D-Lysine hydrobromide Sigma Aldrich Cat# P6407
Phosphate Buffered Saline (PBS) Sigma Aldrich Cat# D8537
Opti-MEM reduced serum medium ThermoFisher Scientific Cat# 11058021
Dithiothreitol (DTT) ThermoFisher Scientific Cat# R0862
Formic acid Fisher Chemical Cat# F/1900/PB15
Acetonitrile Sigma-Aldrich Cat# 34851
Paraformaldehyde (PFA) Sigma Aldrich Cat# F8775
Glycine Sigma Aldrich Cat# G8898
Chicken Serum Sigma Aldrich Cat# C5405
Immersol 518F (30C) oil Zeiss Cat# 444970-9000-000
Hoechst Nuclear Stain (H33342) Sigma Aldrich Cat# B2261
Purified NanoLuciferase Veprintsev Lab Gifted by Bradley Hoare
Critical commercial assays
Nano-Glo luciferase assay system
(Furimizine)
Promega Corporation Cat# N1130
AlphaLISA SureFire Ultra p-STAT3 (Tyr705)
Assay Kit
Perkin Elmer Cat# ALSU-PST3
Experimental models: Cell lines
Human: HEK293T cells (female) ATCC (Virginia, USA) Cat# CRL-3216
Recombinant DNA
IL6SS-NL-IL12Rb1 Genscript Custom synthesis
IL6SS-NL-IL23R Genscript Custom synthesis
IL6SS-HT-TEV-IL12Rb1 Genscript Custom synthesis
IL6SS-HT-TEV-IL23R Genscript Custom synthesis
IL23R-MycDDK expression plasmid Origene Cat# RC211477
IL12Rb1 expression plasmid Origene Cat# SC303661
(Continued on next page)
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RESOURCE AVAILABILITY
Lead contact
Requests for resource and reagent sharing should be directed to and will be fulfilled by the lead contact, Professor Stephen J Hill
(Stephen.hill@nottingham.ac.uk).
Materials availability
All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer
Agreement.
Data and code availability
This study did not generate/analyze any computational datasets/code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Female HEK293T cells were cultured and transfected as described in Method details.
METHOD DETAILS
Materials
All reagents unless otherwise stated were purchased from Sigma-Aldrich. Xba1 and Xho1 restriction enzymes, pNLF and FuGENE
HD transfection reagent, pNLF vectors, NanoGlo Substrate, AF488 HaloTag Ligand and HaloTag NanoBRET 618 Ligand were
purchased fromPromega. OptiMEMandNHSEster linked 5 and 6-Carboxytetramethylrhodamine (TAMRA)mixed isomers were pur-
chased from Thermo-Fisher Scientific. SNAP-Surface Alexa Fluor 488 was purchased from New England BioLabs. An IL23R-
MYCDDK expression plasmid (accession code NM_144701) and an IL12Rb1 expression plasmid (accession code NM_005535)
were purchased fromOrigene. Recombinant NanoLuciferase expressed in E. coli and purified using an N terminal His-tag was gifted
by Bradley Hoare of the Veprintsev lab, University of Nottingham. Rabbit anti-Nanoluciferase was kindly gifted by Promega. Recom-
binant IL-23 protein was gifted by Surjit Bains at GlaxoSmithKline (Stevenage, UK). The protein was originally purified through
expression in HEK293-F cells via co-transduction with BacMam viruses containing the p19-His and p40 transcripts. Heterodimeric
IL-23 was then purified from the supernatant using a Ni-Sepharose column.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
pc 3.1 zeo SigSNAP-tag (Gherbi et al., 2015) Custom synthesis
pc3.1 zeo Invitrogen Cat# V86020
Software and algorithims
GraphPad Prism 7.02 GraphPad Software www.graphpad.com
Zen 2012 Zeiss www.zeiss.com
MaxEnt1 4.1 Waters www.waters.com
ImageJ Fiji 1.53 National Institute of Health www.fiji.sc
Other
White 96-well plates Greiner Bio-One Cat# 655098
Poroshell 300SB-C3 column Agilent Cat# PN 821075-924
PD10 column Cytiva Cat# 17085101
Nunc Lab-Tek 8-well chambered coverslips ThermoFisher Scientific Cat# 1554411
35 mm glass bottom dish MatTek Cat# P35G-1.5-14-C
384 well white Optiplate Perkin Elmer Cat# 6007290
Xba1 restriction enzyme Promega Corporation Cat# R6181
Xho1 restriction enzyme Promega Corporation Cat# R6161
T4 Ligase New England BioLabs Cat# M0202S
DAM negative E. coli Agilent Technologies Cat# 200247
DH5 alpha E. coli Invitrogen Cat# 18265017
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Molecular biology
Construction of N-terminal fusion constructs
NL constructs were custommade at Genscript by synthesis of either IL23R or IL12Rb1 without their endogenous signal peptides and
the subsequent sub-cloning of these, into a pNLF vector (Promega) using Xho1 and Xba1, which previously had an IL-6 secretion
signal added to the N terminus of NanoLuc viamutagenesis. The resulting open reading frames encoded anN-terminal IL-6 secretion
signal followed by NL then a Gly-Ser-Arg linker between the NL fusion and the N terminus of either IL23R or IL12Rb1. HaloTag con-
structs were custom synthesised at Genscript by synthesis of cDNA encoding an N-terminal IL-6 secretion signal followed by
HaloTag which was fused to either IL23R or IL12Rb1 by a Glu-Pro-Thr-Thr-Glu-Asp-Leu-Tyr-Phe-Gln-Ser-Asp-Asn linker that con-
tained a Tobacco Etch Virus (TEV) protease site. These cDNAs were then sub cloned into pNLF plasmids via Nhe1 and Not1 restric-
tion sites.
N-terminal SNAP-tag constructs were created by sub cloning IL23R and IL12Rb1 genes from the previously outlined N-terminal
NanoLuc fusion plasmids (grown in DAM negative E. coli) into a pc3.1 zeocin vector with and N-terminal SNAP-tag fused with a mu-
rine 5-HT3a receptor signal sequence, that has previously been described (Gherbi et al., 2015), using the restriction sites Xho1 and
Xba1. This resulted in a linker between SNAP-tag and the gene with a sequence of Ser-Thr-Ser-Pro-Val-Trp-Trp-Asn-Ser-Ala-Asp-
Ile-Gln-His-Ser-Gly-Gly-Arg-Ser-Arg.
Labelling of purified IL-23 protein
Recombinant IL-23 was labelled by incubation of 100 mg of protein with a 3 times molar ratio (21.4 mM) of NHS ester coupled TAMRA
dye, at room temperature for 2 hours in a pH 7.4 Phosphate Buffered Saline (PBS) buffer. The labelled protein was separated from the
reaction mixture through elution in a PD10 desalting column (Cytiva). Absorbance of the fractions at both 280 and 557 nm was then
quantified through the use of a Nanodrop Spectrophotometer (ThermoFisher Scientific) and combined into aliquots of varying IL-23
concentrations (as defined by 280 nm absorbance).
LC-MS analysis of TAMRA labelled IL-23 cytokine
Unfolding intact mass experiments were carried out using liquid chromatography coupled mass spectrometry (LC-MS). Samples
were analysed on Reversed-Phase (RP) chromatography (BioResolve RP column (2.1 x 50 mm, 2.7 mM, PN: on BioAccord RDa sys-
tem (Waters). Sampleswere desalted bywashingwith 0.1% formic acid in 25%acetonitrile and eluted using linear gradient with 0.1%
formic acid up to 80% acetonitrile at a flow rate of 0.5 ml/min. The divert valve was used and directed flow to waste from 0 to 0.5 min
after injection to avoid source contamination with buffer components. The eluate was ionised by electrospray ionisation (ESI). The
column temperature was maintained at 80C, RDa acquisition was set to high mass range (400-7000 m/z) in positive ion mode
with the following source settings: cone voltage - 70 V, capillary voltage - 1.5 kV and the desolvation temperature - 550C.
Non-reduced samples were injected into LC-MS directly from the stock buffer, when samples were run reduced, 50 mM final con-
centration of DTT was added to sample prior to injection. Chromatography peaks were integrated between 0.5 and 1.5min andmass
spectra were deconvolved using the MaxEnt1 algorithm.
Fluorescence correlation spectroscopy analysis of IL23-TMR
Solution Fluorescence Correlation Spectroscopy (FCS) was carried out as previously described (Briddon et al., 2004; Kilpatrick et al.,
2017). Briefly samples were imaged in 8 well chambered Nunc Labtek coverglasses (No. 1.0 borosilicate glass bottom; ThermoFisher
Scientific) using a Zeiss LSM 880 microscope with a 40X c-Apochromat 1.2 NA water-immersion objective (Zeiss) at 24C. Samples
were excited with a Diode pumped solid state (DPSS) 561 nm laser and emission light collected through a 553-695 nm band pass
onto a GaAsP detector using a pinhole set at 1 airy unit. The confocal volume was set to 200 mm above the coverslip surface and
beam paths were calibrated using a solution of 20 nM TAMRA (5-6 carboxy mixed isomers; D = 2.88 x 10-10 m2/s; ) prepared in
high performance liquid chromatography grade water (Chromasolv ). Calibration measurements were collected using ten 10 s
and a one 60 s reads. FCS measurements were performed using a range of IL23-TMR concentrations in PBS with or without
1 mg/ml protease-free BSA . Measurements were recorded at 1 kW/cm2 laser power for four 15 s reads.
Cell culture
Human Embryonic Kidney 293T (HEK293T) cells were purchased from ATCC and cultured in Dulbecco’s Modified Eagle Medium
(DMEM) with 10% Fetal Bovine Serum (FBS) in tissue culture flasks at 37.5C and 5% CO2. All experimental incubations outlined
in DMEM based media were carried out at 37.5C and 5% CO2 and incubations in Hanks Balanced Saline Solution (HBSS) based
media were carried out 37.5C without added CO2.
Transient transfections
For all experiments except those where transfection conditions were varied to induce changes in intra-receptor NanoBRET, cells
were transfected as follows; HEK293T cells were seeded in six well plates and incubated for 4-6 hours followed by addition of
100 ml of a transfection mixture consisting of FuGENE HD at a 3:1 ratio to DNA plasmid in OptiMEM. 2 mg per well total DNA concen-
tration with 1 mg of NL fused receptor construct and either 1 mg of untagged partner receptor or pc3.1 zeocin plasmid to normalise
DNA concentrations was used in all experiments except NL- IL12Rb1 and IL23R binding experiments where a 1:10 ratio was used
with 2.2 mg of total DNA per well cells were then incubated overnight.
In intra-receptor NanoBRET experiments with a range of transfection conditions HEK293T cells were adjusted to 150000 cells/ml
and dispensed at 100 ml into a poly-d-lysine (PDL) coated 96 well white microplate. Cells were then incubated overnight before being
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transfected with 50 ng well NL-IL23R and varying concentrations of SNAP-IL12Rb1 made up to 100ng/well with pc3.1 zeocin vector
and with 0.3 ml FuGENE per well. The transfection mixture was made up to 5 ml per well with OptiMEM. Cells were then incubated
overnight.
For 8 well imaging experiments HEK293T cells were seeded at 200000 cells per well in 300 ml of media into PDL coated 8 well glass
plates. The following day eachwell was transfectedwith a 10 ml transfectionmixmade up of 200 ng cDNA consisting of 100 ng of each
receptor construct and 0.6 ml of FuGENE HD in OptiMEM. 100 ng of pc3.1 zeocin empty vector was included if only one receptor
monomer was to be expressed.
Luminescence imaging
HEK293T cells were transfected as described in the transient transfection section except for their initial seeding into PDL coated
35mm glass bottom plates (Matek) at a density of 150000 cells/ml in 2 ml of DMEM with 10% FBS. After transfection the dishes
were incubated for 2 days before media was replaced with 3 ml of 37CHBSSwith 5.13 mMFurimizine. The dishes were then imaged
on an LV200 luminescence microscope (Olympus) equipped with a C9100-23B IMAGE EMX2 camera (Hamamatsu) in both bright-
field and luminescence settings using a 60x/1.42NA oil immersion objective lens and 0.5x tube lens. Exposure was adjusted to the
level of expression (2-15 s).
Immuno-cytochemical imaging
HEK293T cells were seeded and transfected in 8 well glass bottom plates as described in the transient transfection section. The
following day cells were washed with PBS and fixed with 3% Paraformaldehyde (PFA) for 15 minutes. The cells were then washed
three times with PBS and incubated with 30 mg/ml BSA and 10 mg/ml Glycine in PBS for 30 minutes. The cells were washed three
times with PBS and then incubated in 10% chicken serum in PBS for 30 minutes. This mixture was then replaced with 1000 fold
diluted rabbit anti-NanoLuciferase antibody in PBS with 10% chicken serum. The plates were then incubated overnight at 4C.
The following day the cells were washed three times with PBS and a 500 fold dilution of AF488 labelled chicken anti-rabbit antibody
(ThermoFisher Scientific) in PBS with 10% chicken serum was added. Following an hour long incubation, cells were washed three
times with PBS and 2mg/ml Hoechst nuclear stain in PBSwas added. The plates were incubated for 10minutes, washed three times
with PBS and then imaged using a Zeiss LSM 880 microscope fitted with a 63x PlanAprochromat oil objective (1.4 NA, Zeiss), using
an Argon 488 nm laser (2%) and a 405-30 nm diode laser (2%) for excitation. The pinhole was set at 1 Airy Unit and AF488 and
Hoescht imaged on separate tracks using a 488 nm beamsplitter and 495-630 nm band pass or a 405 nm beamsplitter and a
410-495 nm band pass respectively. All images were taken with 1024 x1024 pixels per frame with 8 averages.
NanoBRET IL23-TMR ligand binding and competition experiments
Transfected HEK293T cells were incubated overnight before being re-suspended, adjusted to 200000 cells/ml and added to PDL
coated 96 well white clear bottom assay microplates (Griener Bio-One) at 100 ml per well. The plates were then incubated overnight
before media was removed the following day and replaced with 50 ml per well of IL23-TMR in HBSS with 1 mg/ml BSA either with or
without an excess unlabelled IL-23 to quantify non-specific binding, in ligand binding experiments. The concentration used de-
pended on the potency of the interaction, 50 nM was used in NL-IL23R and IL12Rb1 expression experiments, 100 nM in NL-
IL12Rb1 and IL23R experiments and 1 mM in NL-IL23R or NL-IL12Rb1 experiments. In competition experiments media was replaced
with 50 ml per well of a concentration titration of IL-23 in HBSS with 1 mg/ml BSA and differing concentrations of IL23-TMR. Plates
were then incubated for 1 hour before the addition of 5 ml of 77 mMFurimizine per well a further 2minute incubation before reading the
plate on a Pherastar FS plate reader (BMG labtech) using a 450 nm (30 nm bandpass) and >550 nm filter with gains of 2000 and 3000
respectively.
Intra-receptor NanoBRET
To measure agonist induced changes in intra-receptor NanoBRET with a titration of IL-23, HEK293T cells that had previously been
transfected were re-suspended and adjusted to 200000 cells/ml. Cells that expressed HaloTag fused constructs then had 100 nM
HaloTag 618 ligand added. All cells were then dispensed at 100 ml into PDL coated 96 well white clear bottom microplates.
On the day of the experimental read cells transfected with SNAP-tag fused constructs hadmedia replacedwith 50 ml of DMEMwith
FBS with 0.2 mM SNAP-tag-AF488 membrane impermeant substrate and were then incubated for 30 minutes followed by three
washes with HBSS. The buffer for the labelled cells was then replaced with HBSS with 1 mg/ml BSA with or without varying concen-
trations of IL-23 and incubated for one hour. 5 ml of 77 mMFurimizine per well was then added and a further 2minute incubation before
plates were read using a Pherastar FS. Cells labelled with SNAP-tag AF488 substrate
were read using 475 nm (30 nm bandpass) and 535 nm (30 nm bandpass) filters with gains of 2800 and 3600 respectively. Cells
labelled with Halotag 618 dye were read using 460 nm (80 nm bandpass) and >610 nm longpass filters with gains of 2000 and 3000
respectively.
When a range of transfections was being used to measure constituitive association of IL-23 receptor subunits the protocol was
performed as above except that cells were first read for fluorescent intensity before the addition of Furimizine using excitation at
485 nm and emission at 520 nm measured using a PheraStar FS.
Quantification of STAT3 phosphorylation
Transfected HEK293T cells were plated into a PDL coated 96 well tissue culture microplate and then incubated overnight. The
following day media was replaced with serum free DMEM and the cells incubated for 3 hours. Media was then replaced with
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HBSS containing 1 mg/ml BSA and a concentration titration of IL-23 and the cells incubated for 30 minutes. An AlphaLISA SureFire
Ultra assay was then used to measure STAT3 phosphorylation at residue Tyr705. Assays were performed according to the manu-
facturers’ instructions.
Imaging of SNAP-tag and HaloTag fused constructs
HEK293T cells were seeded and transfected in 8 well glass bottom plates as outlined in the transient transfection section. The
following day cells were washed with PBS and then labelled with 500 nM of either AF488 HaloTag ligand or SNAP-tag AF488 sub-
strate in HBSS and incubated for 30minutes at 37C. The cells were then washed three timeswith HBSS and fixed by incubation with
3%PFA in PBS for 15minutes. The cells were then washed twice with PBS and then incubated with 2mg/ml Hoechst stain in PBS for
10 minutes. The cells were then washed three times with PBS before being imaged on a Zeiss LSM 880 microscope as previously
described in the immuno-cytochemical imaging section.
NL and SNAP-AF488 substrate standard curves
Serial dilutions of purified NL enzyme or SNAP-AF488 substrate weremade up in 50 ml HBSSwith 0.1%BSA in white clear bottom 96
well microplates. The plate containing the NL titration had 5 ml of 77 mMFurimizine added to eachwell andwas then incubated at 37C
for 4 minutes. Both plates were then read on the same Pherastar plate reader used in cellular NanoBRET experiments, using the
equivalent settings.
QUANTIFICATION AND STATISTICAL ANALYSIS
The LC-MS data was analysed using UNIFI v1.9.4 (Waters). Mass spectra of multiply charged state species were de-convoluted to
produce mass output using the MaxEnt1 algorithm to the closest Da.
FCS analysis was carried out with Zen Black 2012 software (Zeiss). IL23-TMRautocorrelation datawere fitted to a one-component,
free 3D, Brownian diffusionmodel including a pre-exponential for triple state of the fluorophore (Kilpatrick et al., 2017). IL23-TMRdata
were also fitted to a two component photon counting histogram (PCH) model to derive the ratio of mono to multi-labelled particles. A
20 ms bin time was used for PCH analysis with the first order correction set to the value determined in the calibration measurements
on each experimental day.
Scale bars were added to luminescence imaging data using Fiji version 1.53 (NIH).
Data were exported from a Pherastar plate reader as a BRET ratio, generated by dividing the acceptor signal at 535 ± 30, <550 or
<610 nm by the donor signal at 475 ± 30, 450 ± 30 or 460 ± 80 nm respectively, depending on the filter used.
All further data analysis, including statistical tests, was carried out using Prism 7.02 software (GraphPad). Affinity measures for
IL23-TMR were determined by fitting specific and non-specific binding to the equation:
BRET ratio =
Bmax½B
ð½B+KdÞ + ððA½BÞ + C

where Bmax is the maximal specific binding, [B] is the concentration of IL23-TMR, Kd is the dissociation constant, A is the slope of the
non-specific binding component and C is the Y intercept.
IL23-TMR binding comparison and ligand induced N terminal proximal change traces were generated by normalising the data to




where Bmax is themaximal signal of the curve, [B] is the concentration of the ligand andKd is the dissociation constant of the ligand. In






Where Bmax1, Bmax2, Kd1 and Kd2 are maximal specific binding levels and Kd values of the two components. Comparison of fits
were made by analysis of the residual sum of squares using the partial F-test (GraphPad Prism).
Competition and STAT3 phosphorylation experiments were analysed by fitting the data with the 4 parameter equation:
Y = Bmin +
Bmax  Bmin
1+ 10ðLogXC50½AÞC
where Bmax is themaximal signal, Bmin is theminimum signal, LogXC50 is the log of the compound’s 50% inhibitory concentration for
competition experiments and 50% activating concentration in STAT3 reporter experiments, [A] is the concentration of competing
drug and C is the Hill slope of the curve.
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where Kd is the dissociation constant calculated for IL23-TMR previously in the ligand binding experiments and [L] is the concentra-
tion of IL23-TMR used.
Linear regression analysis was also performed on the relationship between IC50 and IL23-TMR concentration using a variant of the
Cheng-Prusoff equation:
IC50 = ½Lx Ki
Kd
+Ki
Where a plot of IC50 versus [L] yielded a slope of Ki/Kd and the intercept provided Ki.
ll
OPEN ACCESSArticle
Cell Chemical Biology 28, 1–11.e1–e6, October 21, 2021 e6
Please cite this article in press as: Lay et al., Probing the binding of interleukin-23 to individual receptor components and the IL-23 heteromeric re-
ceptor complex in living cells using NanoBRET, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.05.002
